Dana Kaitlyn N, Hertig John B, Weber Robert J
Hosp Pharm. 2017 Feb;52(2):155-159. doi: 10.1310/hpj5202-155.
As spending on medications in the United States increases with each passing year, the need for drug pricing transparency by manufacturers also increases. Drug spending, excluding rebates and discounts, was $309.5 billion in 2015, up 8.5% from 2014. Drug pricing transparency has been a topic of debate across the health care system. This column reviews the issue of drug pricing and emphasizes the need for transparency in this area. We will discuss factors that influence drug pricing, policies and ways to reduce the rising costs of drugs, and the role of pharmacy leaders in managing this problem. A multitude of factors are driving the country to spend more and more on medications; pharmacy leaders can employ various strategies to counteract this escalation of drug prices. After reviewing this article, the pharmacy director will have an increased ability to address drug pricing issues with stakeholders as they develop patient-centered pharmacy services.
随着美国药品支出逐年增加，制药商对药品定价透明度的需求也在增加。2015年，不含回扣和折扣的药品支出为3095亿美元，比2014年增长了8.5%。药品定价透明度一直是整个医疗保健系统争论的话题。本专栏回顾了药品定价问题，并强调了该领域透明度的必要性。我们将讨论影响药品定价的因素、降低药品成本上升的政策和方法，以及药房负责人在解决这一问题中所起的作用。众多因素促使该国在药品上的支出越来越多；药房负责人可以采用各种策略来应对药品价格的这种上涨。读完本文后，药房主任在制定以患者为中心的药房服务时，将更有能力与利益相关者解决药品定价问题。
